THIRD-GENERATION LAY BARGE WILL SPEED NORTH SEA LINE WORK.

被引：0
|
作者：
Lagers, G.H.G.
Bell, C.R.
机构：
来源：
| 1600年 / 72期
关键词：
Compendex;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
PETROLEUM PIPELINES
引用
收藏
相关论文
共 49 条
  • [41] "Knowledge I seek because culture doesn't work anymore ... It doesn't work, death comes": the experiences of third-generation female caregivers (gogos) in South Africa discussing sex, sexuality and HIV and AIDS with children in their care
    Simmonds, Jane E.
    Parry, Charles D. H.
    Abdullah, Fareed
    Burnhams, Nadine Harker
    Christofides, Nicola
    BMC PUBLIC HEALTH, 2021, 21 (01)
  • [42] “Knowledge I seek because culture doesn’t work anymore … It doesn’t work, death comes”: the experiences of third-generation female caregivers (gogos) in South Africa discussing sex, sexuality and HIV and AIDS with children in their care
    Jane E. Simmonds
    Charles D. H. Parry
    Fareed Abdullah
    Nadine Harker Burnhams
    Nicola Christofides
    BMC Public Health, 21
  • [43] Furmonertinib in combination with bevacizumab and intrathecal chemotherapy as later-line re-challenge treatment in EGFR emutated NSCLC patients with leptomeningeal metastasis after third-generation EGFR-TKIs treatment failure
    Cun, F. S.
    Zhao, M.
    Wang, X.
    Xu, T.
    ANNALS OF ONCOLOGY, 2023, 34 : S1691 - S1692
  • [44] Consolidative Stereotactic Radiotherapy in Metastatic EGFR-Mutant Non-Small Cell Lung Cancer Receiving First-Line Third-Generation EGFR Tyrosine Kinase Inhibitors: A Prospective Phase II Trial
    Zhou, Y.
    Ni, J.
    Zhu, Z.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : S94 - S94
  • [45] Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non- small-cell Lung Cancer: A Retrospective Analysis
    Mitsuya, Sho
    Tsuruoka, Kenjiro
    Kanaoka, Kiyoe
    Funamoto, Tomoya
    Tsuji, Hiroyuki
    Matsunaga, Ninso
    Nakamura, Takahiko
    Tamura, Yosuke
    Imanishi, Masafumi
    Ikeda, Soichiro
    Fujisaka, Yasuhito
    Goto, Isao
    Imagawa, Akihisa
    ANTICANCER RESEARCH, 2021, 41 (10) : 5137 - 5145
  • [46] The safety and efficacy of EGFR TKIs monotherapy versus single-agent chemotherapy using third-generation cytotoxics as the first-line treatment for patients with advanced non-small cell lung cancer and poor performance status
    Liu, Shan
    Wang, Deqiang
    Chen, Bo
    Wang, Yan
    Zhao, Weihong
    Wu, Jianqing
    LUNG CANCER, 2011, 73 (02) : 203 - 210
  • [47] First-in-human phase I study of PF-06747775, a third-generation mutant selective EGFR tyrosine kinase inhibitor (TKI) in metastatic EGFR mutant NSCLC after progression on a first-line EGFR TKI
    Husain, H.
    Martins, R. G.
    Goldberg, S. B.
    Senico, P.
    Ma, W.
    Masters, J.
    Pathan, N.
    Kim, D-W.
    Socinski, M. A.
    Goldberg, Z.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2017, 28
  • [48] Befotertinib in first-line treatment for Chinese non-small cell lung cancer patients harboring common EGFR-mutations reveals similar efficacy to other third-generation EGFR-TKIs but somewhat different safety profile
    Sorensen, Jens Benn
    Santoni-Rugiu, Eric
    Urbanska, Edyta Maria
    CHINESE CLINICAL ONCOLOGY, 2024, 13 (06) : 1 - 4
  • [49] Safety and efficacy fi cacy of consolidative stereotactic radiotherapy for oligo-residual EGFR-mutant non-small cell lung cancer after fi rst-line third-generation EGFR-tyrosine kinase inhibitors: a single-arm, phase 2 trial
    Zhou, Yue
    Peng, Lin
    Liang, Fei
    Chu, Li
    Chu, Xiao
    Yang, Xi
    Zhang, Junhua
    Guo, Tiantian
    Jiang, Shanshan
    Pang, Yechun
    Wang, Zezhou
    Zhang, Li
    Ni, Jianjiao
    Zhu, Zhengfei
    ECLINICALMEDICINE, 2024, 76
12345